Gene · 1452
CSNK1A1: casein kinase 1 alpha 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CSNK1A1: casein kinase 1 alpha 1. Genes, record 1452. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1452
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P48729 | Casein kinase I isoform alpha | 337 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents29
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 40152 | P48729 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9974 | P48729 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9974 | P48729 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 12054 | P48729 | Espacenet |
| EP 4522752 A1 | 2025-03-19 | 17 | P48729 | Espacenet |
| EP 4490275 A1 | 2025-01-15 | 7 | P48729 | Espacenet |
| US 11785925 B2 | 2023-10-17 | 13 | P48729 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 12054 | P48729 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 115025 | P48729 | Espacenet |
| US 11168345 B2 | 2021-11-09 | 5 | P48729 | Espacenet |
1 to 10 of 29
See all 29 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,666
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CSNK1A1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 17 | 2025 |
| R01CA214608 | The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase | 16 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 13 | 2025 |
| R35GM122516 | Maximizing Investigators' Research Award (R35 - Clinical Trial Optional) | 12 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 10 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 9 | 2025 |
| R01CA218278 | Degrading therapeutically important kinases using small molecules | 8 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 7 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
1 to 10 of 1,666Source NIH's project files
See all 1,666 nih grantsPapers2,578
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chemical regulation of circadian rhythms through inhibition of casein kinase Iδ and α. | Biochem Biophys Res Commun | 2026 | 42810220 | PubTator, text mining | PubMed |
Midazolam Reduces Metabolic Viability and Induces Apoptosis in MIA PaCa-2 Pancreatic Cancer Cells with Selective Transcriptional Modulation of Wnt and Hedgehog Components: A Preliminary In Vitro Study. | Pharmaceuticals (Basel) | 2026 | 42797517 | PubTator, text mining | PubMed |
| Systematic Analysis of MRTFB Phosphoproteomic Datasets Reveals Co-Regulated Kinase Networks and Co-Occurring Phosphosites Associated with the Actin Cytoskeleton Pathway. | Curr Issues Mol Biol | 2026 | 42793267 | PubTator, text mining | PubMed |
| Lenalidomide Exposure and TP53-Mutated Myelodysplastic Syndromes/Neoplasms. | Curr Oncol | 2026 | 42782853 | PubTator, text mining | PubMed |
| Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms. | Leukemia | 2026 | 42693162 | PubTator, text mining | PubMed |
| Casein Kinase 1 Alpha 1 Is Over-expressed in Pancreatic Adenocarcinoma Tissues and Correlates With Shorter Patient Survival. | Cancer Diagn Progn | 2026 | 42682938 | PubTator, text mining | PubMed |
| CCT8 associates with the MYO10 motor domain and regulates filopodia and breast cancer cell invasion. | J Cell Sci | 2026 | 42677351 | PubTator, text mining | PubMed |
| Discovery of molecular glue degrader for treatment of IMiDs-resistant multiple myeloma based on GLUT-mediated tumor targeting strategy. | Bioorg Chem | 2026 | 42561560 | PubTator, text mining | PubMed |
| The kinase CK1α coordinates the initiation and termination of the cGAS-STING pathway. | Cell Death Differ | 2026 | 42557374 | PubTator, text mining | PubMed |
| A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells. | Cancer Res | 2026 | 42545171 | PubTator, text mining | PubMed |
1 to 10 of 2,578
See all 2,578 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1452
GET https://conductscience.org/api/genes/v1/1452/patents?page=2